Related Experiment Video
Updated: Mar 25, 2026
In Vitro Method to Control Concentrations of Halogenated Gases in Cultured Alveolar Epithelial Cells
Published on: October 23, 2018
Erythropoietin diminishes isoflurane-induced apoptosis in rat frontal cortex
Elvan Ocmen1, Abdurrahim Derbent2, Serap C Micilli3
1Department of Anesthesiology and Reanimation, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
Insights
Erythropoietin (EPO) administration significantly reduced isoflurane-induced neuroapoptosis in rat pups. This finding suggests EPO
Area of Science:
- Neuroscience
- Anesthesiology
- Developmental Biology
Background:
- Anesthetic drugs, such as isoflurane, can induce cellular and behavioral changes in the developing brain during critical growth periods.
- Investigating neuroprotective agents is crucial to mitigate potential harm from anesthesia in young organisms.
Purpose of the Study:
- To evaluate the neuroprotective efficacy of erythropoietin (EPO) in preventing isoflurane-induced neuroapoptosis in neonatal rats.
- To assess the impact of EPO on learning and memory functions following anesthetic exposure.
Main Methods:
- Wistar rat pups (7 days old) were exposed to isoflurane anesthesia for 6 hours.
- Erythropoietin (1000 IU·kg-1, IP) was administered post-anesthesia in the treatment group.
- Neuroapoptosis was quantified using silver, caspase-3, and fluoro-jade C staining in various brain regions.
- Learning and memory were assessed using the Morris water maze.
Main Results:
- Isoflurane anesthesia significantly increased apoptotic cell counts in the frontal cortex compared to controls.
- Erythropoietin administration significantly reduced isoflurane-induced neuroapoptosis in the frontal cortex.
- While EPO reduced apoptosis, further studies are needed to determine optimal dosage and timing for clinical application.
Conclusions:
- Erythropoietin demonstrates a significant neuroprotective effect against isoflurane-induced neuroapoptosis in developing rat brains.
- The findings support further investigation into EPO's therapeutic potential in pediatric anesthesia contexts.
- Optimal dosing and administration timing of EPO require further experimental validation before clinical practice.
Background:
During the brain growth spurt, anesthetic drugs can cause cellular and behavioral changes in the developing brain. The aim of this study was to determine the neuroprotective effect of erythropoietin after isoflurane anesthesia in rat pups.
Methods:
A total of 42, 7-day-old Wistar rats were divided into three groups. Control group (GC; n = 14): Rats breathed 100% oxygen for 6 h; Isoflurane group (GI; n = 14): Rats were exposed to 1.5% isoflurane in 100% oxygen for 6 h; Isoflurane + erythropoietin group (GIE; n = 14): 1000 IU·kg(-1) (intraperitoneal; IP) Erythropoietin was administered after isoflurane anesthesia. Each group was divided into two groups for pathology and learning and memory tests. Silver, caspase-3, and fluoro-jade C staining were used for detecting apoptotic cells in frontal cortex, striatum, hippocampus, thalamus, and amygdala. Morris water maze was used to evaluate learning and memory.
Results:
There was a significant increase in apoptotic cell count after isoflurane anesthesia in the frontal cortex when compared with control group (29.0 ± 9.27 vs 3.28 ± 0.75 [P = 0.002], 20.85 ± 10.94 vs 2.0 ± 0.81 [P = 0.002] and 24.57 ± 10.4 vs 5.14 ± 0.69 [P = 0.024] with silver, caspase-3, and fluoro-jade C staining, respectively). The apoptotic cell count in the frontal cortex was significantly higher in GIE than GC with caspase-3 staining (9.14 ± 3.13 vs 2.0 ± 0.81, P = 0.002). The apoptotic cell count in GIE was significantly reduced in the frontal cortex when compared with GI (4.0 ± 0.81 vs 29.0 ± 9.27 [P = 0.002], 9.14 ± 3.13 vs 20.85 ± 10.94 [P = 0.04] and 4.0 ± 1.63 vs 24.57 ± 10.4 [P = 0.012] with silver, caspase-3, and fluoro-jade C staining, respectively).
Conclusions:
A total of 1000 IU·kg(-1) IP erythropoietin diminished isoflurane-induced neuroapoptosis. Further experimental studies have to be planned to reveal the optimal dose and timing of erythropoietin before adaptation to clinical practice.
